

**Krintafel (tafenoquine)
Effective 02/01/2023**

Plan	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input checked="" type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Krintafel[®] (tafenoquine) is an 8-aminoquinoline antimalarial drug FDA-approved for the radical cure (prevention of relapse) of malaria caused by *P. vivax* in patients aged 16 years and older who are concurrently receiving chloroquine therapy.

No PA	Require PA
Krintafel [®] (tafenoquine) ≤ 2 units/year	Krintafel [®] (tafenoquine) > 2 units/year
Coartem (artemether/lumefantrine) ≤ 24 units/year	
chloroquine phosphate tablet	
malarone # (atovaquone/proguanil)	
mefloquine	
Mepron # (atovaquone)	
Plaquenil # (hydroxychloroquine)	
primaquine	

This is a brand-name drug with FDA "A"-rated generic equivalents. PA is required for the brand, unless a particular form of that drug (for example, tablet, capsule, or liquid) does not have an FDA "A"-rated generic equivalent.

Coverage Guidelines

Authorization may be granted for members when all the following criteria are met, and documentation is provided:

1. Appropriate diagnosis of *Plasmodium vivax* malaria
2. Member is concurrently receiving chloroquine therapy
3. Medical necessity for the requested agent above quantity limits



Limitations

1. Authorizations will be approved for a maximum of 2 tablets (300 mg total) per year.

References

1. Breman JG. Clinical manifestations of malaria in nonpregnant adults and children. In: Daily J (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2017 [cited 2017 July 18]. Available from: <http://www.uptodate.com/utd/index.do>.
2. Centers for Disease Control and Prevention. Malaria Treatment Guidelines, 2013 [guideline on the Internet]. Atlanta (GA): CDC; 2015 [cited 2017 July 18]; Available from: <http://www.cdc.gov/malaria>.
3. Daily J. Treatment of uncomplicated falciparum malaria in nonpregnant adults and children. In: Leder K, Kaplan SL (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2017 [cited 2017 July 18]. Available from: <http://www.uptodate.com/utd/index.do>.
4. Baird JK, Price R. Overview of non-falciparum malaria in nonpregnant adults and children. In: Daily J (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2017 [cited 2017 July 18]. Available from: <http://www.uptodate.com/utd/index.do>.
5. Taylor TE. Treatment of severe falciparum malaria. In: Daily J DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2017 [cited 2017 July 18]. Available from: <http://www.uptodate.com/utd/index.do>.
6. Krintafel® [package insert]. Research Triangle Park, (NC): GlaxoSmithKline; 2020 Nov

Review History

11/20/19 – Reviewed at P&T

11/18/2020- Reviewed at P&T

11/16/2022 – Reviewed for Nov P&T. Separated out MH vs Comm/Exch. Matched MH UPPL. Effective 2/1/23

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.